BioCryst leaves ultra-rare bone disease efforts in hands of Ipsen, Regeneron with discontinuation

With compliments to its peer drugmakers developing other oral ALK-2 inhibitors, BioCryst is stepping back from the effort to produce a therapy for an ultra-rare bone disease—and keeping $100 million in its pocket for other priorities.